MaxCyte MXCT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.65M+32.2% | $7.3M+6.9% | $6.83M-19.7% | $8.51M-18.1% | $10.39M+19.5% | ||
| $1.57M-2.5% | $1.61M+0.9% | $1.6M+5.1% | $1.52M+1.5% | $1.5M-34.4% | ||
| $8.08M+42.0% | $5.69M+8.7% | $5.23M-25.1% | $6.99M-21.4% | $8.89M+38.7% | ||
| 83.7%+5.8pp | 77.9%+1.3pp | 76.6%-5.5pp | 82.1%-3.4pp | 85.6%+11.8pp | ||
| $3.86M+15.7% | $3.34M-37.3% | $5.32M-15.2% | $6.27M+6.2% | $5.9M+27.9% | ||
| $3.43M-2.2% | $3.5M-11.0% | $3.94M-32.0% | $5.79M+1.5% | $5.7M-12.0% | ||
| $5.97M+8.8% | $5.48M-9.1% | $6.03M-25.4% | $8.08M-5.2% | $8.53M+18.3% | ||
| $1.02M-2.4% | $1.04M-0.3% | $1.04M-3.3% | $1.08M+1.8% | $1.06M+4.0% | ||
| —— | $888.5K0.0% | $888.5K0.0% | $888.5K0.0% | $888.5K— | ||
| $14.27M-15.7% | $16.92M-12.7% | $19.38M-8.6% | $21.22M+0.1% | $21.19M+9.7% | ||
| $14.27M-15.7% | $16.92M-12.7% | $19.38M-8.6% | $21.22M+0.1% | $21.19M+9.7% | ||
| -$6.19M+44.9% | -$11.23M+20.7% | -$14.15M+0.5% | -$14.23M-15.7% | -$12.3M+4.7% | ||
| -64.1%+89.7pp | -153.8%+53.4pp | -207.2%-40.0pp | -167.2%-48.9pp | -118.3%+30.1pp | ||
| $1.44M-12.0% | $1.63M-5.9% | $1.73M-7.3% | $1.87M-8.1% | $2.03M-11.7% | ||
| $1.44M-12.0% | $1.63M-5.9% | $1.73M-7.3% | $1.87M-8.1% | $2.03M-11.7% | ||
| -$4.75M+50.5% | -$9.6M+22.7% | -$12.42M-0.5% | -$12.36M-20.4% | -$10.26M+3.2% | ||
| —— | —— | —— | —— | —— | ||
| -$4.75M+50.5% | -$9.6M+22.7% | -$12.42M-0.5% | -$12.36M-20.4% | -$10.26M+3.2% | ||
| -49.2%+82.2pp | -131.5%+50.4pp | -181.8%-36.6pp | -145.3%-46.5pp | -98.8%+23.1pp | ||
| -$0.04+55.6% | -$0.09+25.0% | -$0.120.0% | -$0.12-20.0% | -$0.100.0% | ||
| -$0.04+55.6% | -$0.09+25.0% | -$0.120.0% | -$0.12-20.0% | -$0.100.0% | ||
| 106.9M+0.4% | 106.4M-0.2% | 106.6M+0.2% | 106.4M+0.4% | 106M+1.1% | ||
| 106.9M+0.4% | 106.4M-0.2% | 106.6M+0.2% | 106.4M+0.4% | 106M+1.1% | ||
| —— | $888.5K0.0% | $888.5K0.0% | $888.5K0.0% | $888.5K— | ||
| $1.44M-12.0% | $1.63M-5.9% | $1.73M-7.3% | $1.87M-8.1% | $2.03M-11.7% | ||
| -$6.19M+44.9% | -$11.23M+20.7% | -$14.15M+0.5% | -$14.23M-15.7% | -$12.3M+4.7% | ||
| -$5.14M+49.4% | -$10.15M+22.4% | -$13.08M+0.4% | -$13.13M-17.2% | -$11.2M+5.4% | ||
| -$5.14M+49.4% | -$10.15M+22.4% | -$13.08M+0.4% | -$13.13M-17.2% | -$11.2M+5.4% | ||
| -53.2%+85.9pp | -139.1%+52.4pp | -191.5%-37.2pp | -154.3%-46.5pp | -107.8%+28.5pp | ||
| -$6.19M+44.9% | -$11.23M+20.7% | -$14.15M+0.5% | -$14.23M-15.7% | -$12.3M+4.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is MaxCyte's revenue?
- MaxCyte (MXCT) generated $32.3M in revenue over the trailing twelve months, down 14.3% year over year.
- Is MaxCyte profitable?
- MaxCyte is not currently profitable: it reported a net loss of $39.1M over the trailing twelve months, a -121.2% net margin.
- What are MaxCyte's profit margins?
- Gross margin is 80.5% and operating margin is -141.8%, with a -121.2% net margin.
- What is MaxCyte's earnings per share?
- MaxCyte's diluted EPS over the trailing twelve months is $-0.37.
- Where does MaxCyte's income statement data come from?
- Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
